Skip to main content
Erschienen in: DGNeurologie 1/2020

08.12.2019 | Multiple Sklerose | CME Zertifizierte Fortbildung

Kognition und multiple Sklerose: Hintergründe, Diagnostik und Therapie

verfasst von: Prof. Dr. I.-K. Penner, H. Schreiber

Erschienen in: DGNeurologie | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Zusammenfassung

Kognitive Störungen zählen zu den Schlüsselsymptomen der multiplen Sklerose (MS) und beeinträchtigen Lebensqualität und Berufsfähigkeit in entscheidendem Ausmaß. Sie treten mit einer Prävalenz von 40–50 % auf, können bereits früh im Krankheitsgeschehen diagnostiziert werden und sind weitestgehend unabhängig vom Behinderungsgrad. Das kognitive Kerndefizit umfasst die kognitive Verarbeitungsgeschwindigkeit, das verbale und visuell-räumliche Kurzzeitgedächtnis und Lernen und die mentale Flexibilität (Multitasking). Anzuraten ist, den kognitiven Status bereits bei der Diagnosestellung als individuellen Ausgangswert zu erheben. Mit diesem lässt sich im Verlauf der Erkrankung eine Progression des kognitiven Defizits zuverlässig nachweisen. Als Screeningverfahren wird BICAMS („brief international cognitive assessment for multiple sclerosis“) empfohlen. Die Behandlung der kognitiven Störungen gestaltet sich schwierig.
Literatur
1.
Zurück zum Zitat Rao SM et al (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41:685–691PubMed Rao SM et al (1991) Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 41:685–691PubMed
2.
Zurück zum Zitat Benedict RH et al (2006) Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 12:549–558PubMed Benedict RH et al (2006) Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 12:549–558PubMed
3.
Zurück zum Zitat Khalil M et al (2011) Cognitive impairment in relation to MRI metrics in patients with clinically isolated syndrome. Mult Scler 17:173–180PubMed Khalil M et al (2011) Cognitive impairment in relation to MRI metrics in patients with clinically isolated syndrome. Mult Scler 17:173–180PubMed
4.
Zurück zum Zitat Feuillet L et al (2007) Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 13:124–127PubMed Feuillet L et al (2007) Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 13:124–127PubMed
5.
Zurück zum Zitat Lebrun C et al (2010) Cognitive function in radiologically isolated syndrome. Mult Scler 16:919–925PubMed Lebrun C et al (2010) Cognitive function in radiologically isolated syndrome. Mult Scler 16:919–925PubMed
6.
Zurück zum Zitat Kobelt G et al (2017) New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler 23:1123–1136PubMedPubMedCentral Kobelt G et al (2017) New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler 23:1123–1136PubMedPubMedCentral
7.
Zurück zum Zitat Flachenecker P et al (2017) New insights into the burden and costs of multipe sclerosis: results for Germany. Mult Scler 23:78–90PubMed Flachenecker P et al (2017) New insights into the burden and costs of multipe sclerosis: results for Germany. Mult Scler 23:78–90PubMed
8.
Zurück zum Zitat Amato MP et al (2006) Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol 253:1054–1059PubMed Amato MP et al (2006) Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol 253:1054–1059PubMed
9.
Zurück zum Zitat Calabrese P, Penner IK (2007) Cognitive dysfunctions in multiple sclerosis—a “multiple disconnection syndrome?”. J Neurol 254:18–21 Calabrese P, Penner IK (2007) Cognitive dysfunctions in multiple sclerosis—a “multiple disconnection syndrome?”. J Neurol 254:18–21
10.
Zurück zum Zitat Amato MP et al (1995) Cognitive impairment in early-onset multiple sclerosis: pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol 52:168–172PubMed Amato MP et al (1995) Cognitive impairment in early-onset multiple sclerosis: pattern, predictors, and impact on everyday life in a 4-year follow-up. Arch Neurol 52:168–172PubMed
11.
Zurück zum Zitat Benedict RHB et al (2016) Benchmarks of meaningful impairment on the MSFC and BICAMS. Mult Scler 22:1874–1882PubMed Benedict RHB et al (2016) Benchmarks of meaningful impairment on the MSFC and BICAMS. Mult Scler 22:1874–1882PubMed
12.
Zurück zum Zitat Ruet A et al (2013) Cognitive impairment, health-related quality of life and vocational status at early stages of multiple sclerosis: a 7-year longitudinal study. J Neurol 260:776–784PubMed Ruet A et al (2013) Cognitive impairment, health-related quality of life and vocational status at early stages of multiple sclerosis: a 7-year longitudinal study. J Neurol 260:776–784PubMed
13.
Zurück zum Zitat Pitteri M et al (2017) Cognitive impairment predicts disability progression and cortical thinning in MS: an 8-year study. Mult Scler 23:848–854PubMed Pitteri M et al (2017) Cognitive impairment predicts disability progression and cortical thinning in MS: an 8-year study. Mult Scler 23:848–854PubMed
14.
Zurück zum Zitat Calabrese M et al (2009) Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 66:1144–1150PubMed Calabrese M et al (2009) Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 66:1144–1150PubMed
15.
Zurück zum Zitat Schoonheim MM et al (2015) Network collapse and cognitive impairment in multiple sclerosis. Front Neurol 6:1–5 Schoonheim MM et al (2015) Network collapse and cognitive impairment in multiple sclerosis. Front Neurol 6:1–5
16.
Zurück zum Zitat Langdon DW et al (2012) Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler 18:891–898PubMedPubMedCentral Langdon DW et al (2012) Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler 18:891–898PubMedPubMedCentral
17.
Zurück zum Zitat Smith A (1973) Symbol digit modalities test. Western Psychological Services, Los Angeles Smith A (1973) Symbol digit modalities test. Western Psychological Services, Los Angeles
18.
Zurück zum Zitat Delis DC, Kramer JH, Kaplan E, Ober BA (Hrsg) (2000) California verbal learning test, second edition (CVLT-II). Psychological Corporation, San Antonio Delis DC, Kramer JH, Kaplan E, Ober BA (Hrsg) (2000) California verbal learning test, second edition (CVLT-II). Psychological Corporation, San Antonio
19.
Zurück zum Zitat Helmstaedter C, Lendt M, Lux S (Hrsg) (2001) Verbaler Lern- und Merkfähigkeitstest. Manual. Beltz, Göttingen Helmstaedter C, Lendt M, Lux S (Hrsg) (2001) Verbaler Lern- und Merkfähigkeitstest. Manual. Beltz, Göttingen
20.
Zurück zum Zitat Benedict RH (Hrsg) (1997) Brief Visuospatial memory test-revised (BVMT-R). Psychological Assessment Resources, Lutz Benedict RH (Hrsg) (1997) Brief Visuospatial memory test-revised (BVMT-R). Psychological Assessment Resources, Lutz
22.
Zurück zum Zitat Filser M et al (2018) The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS): results from the German validation study. J Neurol 265:2587–2593PubMed Filser M et al (2018) The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS): results from the German validation study. J Neurol 265:2587–2593PubMed
23.
24.
Zurück zum Zitat Fischer JS et al (2000) Neuropsychological effects of interferon beta-1a in relapsing-remitting multiple sclerosis. Ann Neurol 48:885–892PubMed Fischer JS et al (2000) Neuropsychological effects of interferon beta-1a in relapsing-remitting multiple sclerosis. Ann Neurol 48:885–892PubMed
25.
Zurück zum Zitat Penner IK et al (2012) Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Mult Scler 18(10):1466–1471PubMedPubMedCentral Penner IK et al (2012) Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Mult Scler 18(10):1466–1471PubMedPubMedCentral
26.
Zurück zum Zitat Patti F, Morra VB, Amato MP, Trojano M, Bastianello S, Tola MR et al (2013) Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLoS One. 8(8):e74111PubMedPubMedCentral Patti F, Morra VB, Amato MP, Trojano M, Bastianello S, Tola MR et al (2013) Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLoS One. 8(8):e74111PubMedPubMedCentral
27.
Zurück zum Zitat Kappos L et al (2016) The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology 87(10):978–987PubMedPubMedCentral Kappos L et al (2016) The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology 87(10):978–987PubMedPubMedCentral
28.
Zurück zum Zitat Weinstein A et al (1999) Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 56:319–324PubMed Weinstein A et al (1999) Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 56:319–324PubMed
29.
Zurück zum Zitat Schwid SR et al (2007) Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year trial. J Neurol Sci 255:57–63PubMed Schwid SR et al (2007) Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year trial. J Neurol Sci 255:57–63PubMed
31.
Zurück zum Zitat Sprenger T et al (2017) Evaluation of the long-term treatment effect of Teriflunomide on cognitive outcomes and association with brain volume change: data from TEMSO and its Extension Study. ECTRIMS Online Library, 200340; P682017 Sprenger T et al (2017) Evaluation of the long-term treatment effect of Teriflunomide on cognitive outcomes and association with brain volume change: data from TEMSO and its Extension Study. ECTRIMS Online Library, 200340; P682017
32.
Zurück zum Zitat Cohen J et al (2013) Efficacy of fingolimod in relapsing remitting multiple sclerosis (RRMS) as measured by multiple sclerosis functional composite: results from the TRANSFORMS, FREEDOMS, and FREEDOMS II phase 3 studies. Poster 620. ECTRIMS Online Library. ectrims-congress.eu/ectrims/2013/copenhagen/34100. Cohen J et al (2013) Efficacy of fingolimod in relapsing remitting multiple sclerosis (RRMS) as measured by multiple sclerosis functional composite: results from the TRANSFORMS, FREEDOMS, and FREEDOMS II phase 3 studies. Poster 620. ECTRIMS Online Library. ectrims-congress.eu/ectrims/2013/copenhagen/34100.
33.
Zurück zum Zitat Pelletier J et al (2011) Effect of fingolimod on multiple sclerosis functional composite (MSFC) defined disability progression in patients with relapsing remitting MS (RRMS): results from two phase III studies. Neurology 76:A611 Pelletier J et al (2011) Effect of fingolimod on multiple sclerosis functional composite (MSFC) defined disability progression in patients with relapsing remitting MS (RRMS): results from two phase III studies. Neurology 76:A611
34.
Zurück zum Zitat Comi G et al (2017) Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol 264:2436–2449PubMedPubMedCentral Comi G et al (2017) Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol 264:2436–2449PubMedPubMedCentral
35.
Zurück zum Zitat Weinstock-Guttman B et al (2012) Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol 259:898–905PubMed Weinstock-Guttman B et al (2012) Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol 259:898–905PubMed
36.
Zurück zum Zitat Cohan S et al (2018) Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology 90(15 Suppl):S44.005 Cohan S et al (2018) Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials. Neurology 90(15 Suppl):S44.005
37.
Zurück zum Zitat Amato MP, Goretti B (2018) Pharmacological treatment for cognitive impairment in multiple sclerosis. In: DeLuca J, Sandroff BM (Hrsg) Cognition and behavior in multiple sclerosis. Am Psychol Assoc, Washington DC, S 245–264 Amato MP, Goretti B (2018) Pharmacological treatment for cognitive impairment in multiple sclerosis. In: DeLuca J, Sandroff BM (Hrsg) Cognition and behavior in multiple sclerosis. Am Psychol Assoc, Washington DC, S 245–264
39.
Zurück zum Zitat Benedict RHB et al (2018) Impact of Siponimod on cognition in patients with secondary progressiver Multiple Sclerosis: Results from Phase 3 EXPAND Study (S44.004). Neurology 90(15 Supplement) Benedict RHB et al (2018) Impact of Siponimod on cognition in patients with secondary progressiver Multiple Sclerosis: Results from Phase 3 EXPAND Study (S44.004). Neurology 90(15 Supplement)
40.
Zurück zum Zitat De Giglio L et al (2019) Effect of dalfampridine on Information processing speed impairment in multiple sclerosis. Neurology 93:1–14 De Giglio L et al (2019) Effect of dalfampridine on Information processing speed impairment in multiple sclerosis. Neurology 93:1–14
41.
Zurück zum Zitat O’Brien AR et al (2008) Evidence-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Arch Phys Med Rehabil 89:761–769PubMed O’Brien AR et al (2008) Evidence-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Arch Phys Med Rehabil 89:761–769PubMed
42.
Zurück zum Zitat Plohmann AM et al (1998) Computer-assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 64:455–462PubMedPubMedCentral Plohmann AM et al (1998) Computer-assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 64:455–462PubMedPubMedCentral
43.
Zurück zum Zitat Rosti-Otajärvi EM et al (2013) Neuropsychological rehabilitation has beneficial effects on perceived cognitive deficits in multiple sclerosis during nine-month follow-up. J Neurol Sci 334:154–160PubMed Rosti-Otajärvi EM et al (2013) Neuropsychological rehabilitation has beneficial effects on perceived cognitive deficits in multiple sclerosis during nine-month follow-up. J Neurol Sci 334:154–160PubMed
44.
Zurück zum Zitat Mäntynen A et al (2014) Neuropsychological rehabilitation does not improve cognitive performance but reduces perceived cognitive deficits in patients with multiple sclerosis: A randomised, controlled, multi-centre trial. Mult Scler 20:99–107PubMed Mäntynen A et al (2014) Neuropsychological rehabilitation does not improve cognitive performance but reduces perceived cognitive deficits in patients with multiple sclerosis: A randomised, controlled, multi-centre trial. Mult Scler 20:99–107PubMed
45.
Zurück zum Zitat Chiaravalloti ND, DeLuca J (2018) Cognitive rehabilitation in multiple sclerosis. In: DeLuca J, Sandroff BM (Hrsg) Cognition and behavior in multiple sclerosis. Am Psychol Assoc, Washington DC, S 265–292 Chiaravalloti ND, DeLuca J (2018) Cognitive rehabilitation in multiple sclerosis. In: DeLuca J, Sandroff BM (Hrsg) Cognition and behavior in multiple sclerosis. Am Psychol Assoc, Washington DC, S 265–292
48.
Zurück zum Zitat Sandroff BM, Motl RW (2018) Exercise, physical activitiy, physical fitness and cognition in multiple sclerosis. In: DeLuca J, Sandroff BM (Hrsg) Cognition and behavior in multiple sclerosis. Am Psychol Assoc, Washington DC, S 293–319 Sandroff BM, Motl RW (2018) Exercise, physical activitiy, physical fitness and cognition in multiple sclerosis. In: DeLuca J, Sandroff BM (Hrsg) Cognition and behavior in multiple sclerosis. Am Psychol Assoc, Washington DC, S 293–319
Metadaten
Titel
Kognition und multiple Sklerose: Hintergründe, Diagnostik und Therapie
verfasst von
Prof. Dr. I.-K. Penner
H. Schreiber
Publikationsdatum
08.12.2019
Verlag
Springer Medizin
Erschienen in
DGNeurologie / Ausgabe 1/2020
Print ISSN: 2524-3446
Elektronische ISSN: 2524-3454
DOI
https://doi.org/10.1007/s42451-019-00132-1

Weitere Artikel der Ausgabe 1/2020

DGNeurologie 1/2020 Zur Ausgabe

Arzneimitteltherapie

Therapie der Altersepilepsie